Edition:
United Kingdom

Kura Oncology Inc (KURA.OQ)

KURA.OQ on NASDAQ Stock Exchange Global Select Market

18.45USD
17 Aug 2018
Change (% chg)

$-0.95 (-4.90%)
Prev Close
$19.40
Open
$19.30
Day's High
$19.48
Day's Low
$18.35
Volume
56,076
Avg. Vol
68,613
52-wk High
$24.00
52-wk Low
$5.90

Chart for

About

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood... (more)

Overall

Beta: --
Market Cap(Mil.): $387.63
Shares Outstanding(Mil.): 27.69
Dividend: --
Yield (%): --

Financials

  KURA.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.53 -- --
ROI: -46.24 1.78 14.61
ROE: -52.12 3.28 16.33

BRIEF-Kura Oncology Reports Qtrly Loss Per Share Of $0.46

* KURA ONCOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 May 2018

BRIEF-Kura Oncology Announces New Patent For Tipifarnib In Hematologic Malignancies

* KURA ONCOLOGY ANNOUNCES NEW PATENT FOR TIPIFARNIB IN HEMATOLOGIC MALIGNANCIES

02 May 2018

BRIEF-Kura Oncology Inc - Co Entered Into An Amended And Restated Sales Agreement With Cowen And Company​

* KURA ONCOLOGY INC - ‍ON MARCH 12, 2018, CO ENTERED INTO AN AMENDED AND RESTATED SALES AGREEMENT WITH COWEN AND COMPANY, LLC - SEC FILING​

12 Mar 2018

BRIEF-Kura Oncology Provides Regulatory Update On Tipifarnib

* KURA ONCOLOGY PROVIDES REGULATORY UPDATE ON TIPIFARNIB AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

12 Mar 2018

Earnings vs. Estimates